Quest Diagnostics Incorporated announced that it has received New York approval for ClariSure microarray-based comparative genomic hybridization (aCGH) postnatal test for testing on patients. With the State Department of Health Clinical Laboratory Evaluation Program license, Quest Diagnostics operates one of only three laboratories in the US approved to perform aCGH testing on postnatal samples collected on patients in New York. The ClariSure aCGH postnatal test is approved as an aid in detecting copy-number chromosomal abnormalities implicated in dozens of medical conditions, including mental retardation, birth defects, and autism spectrum and developmental disorders, which conventional laboratory tests may fail to detect. Nichols Institute Scientists have validated the ClariSure test's ability to use a single blood specimen to identify chromosomal abnormalities associated with dozens of disorders, including Down, cri du chat, DiGeorge and Williams syndromes. Using a fluorescence in situ hybridization (FISH) methodology a positive result may be confirmed. Information about the ClariSure postnatal test will be provided by Quest Diagnostics Nichols Institute at its exhibit at the 2009 American College of Medical Genetics (ACMG) conference.